Inhibition of proteasomal glucocorticoid receptor degradation restores dexamethasone-mediated stabilization of the blood-brain barrier after traumatic brain injury

Critical Care Medicine

Volumn 41, Issue 5, 2013, Pages 1305-1315

  Thal, Serge C ^a   Schaible, Eva Verena ^a   Neuhaus, Winfried ^b,c   Scheffer, David ^b   Brandstetter, Moritz ^a   Engelhard, Kristin ^a   Wunder, Christian ^b   Förster, Carola Y ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

blood?brain barrier; bortezomib; dexamethasone; GC receptor; glucocorticoid; nuclear receptor; proteasome; steroids; traumatic brain injury

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; OCCLUDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; CONTROLLED STUDY; ENDOTHELIUM CELL; MALE; MOUSE; NERVE CELL LESION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRAUMATIC BRAIN INJURY;

ANIMALS; BLOOD GAS ANALYSIS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BORONIC ACIDS; BRAIN EDEMA; BRAIN INJURIES; DEXAMETHASONE; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MULTIVARIATE ANALYSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID; REFERENCE VALUES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 84876666485     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31827ca494     Document Type: Article

References (53)

1. Weiss H, Agimi Y, Steiner C: Youth motorcycle-related hospitaliza-tions and traumatic brain injuries in the United States in 2006. Pediatrics 2010; 126:1141-1148
2. Marklund N, Bakshi A, Castelbuono DJ, et al: Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr Pharm Des 2006; 12:1645-1680
3. Narayan RK, Michel ME, Ansell B, et al: Clinical trials in head injury. J Neurotrauma 2002; 19:503-557
4. Roberts I, Yates D, Sandercock P, et al; CRASH trial collaborators: Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically signifcant head injury (MRC CRASH trial): Randomised placebo-controlled trial. Lancet 2004; 364:1321-1328
5. Donkin JJ, Vink R: Mechanisms of cerebral edema in traumatic brain injury: Therapeutic developments. Curr Opin Neurol 2010; 23:293-299
6. Klatzo I: Evolution of brain edema concepts. Acta Neurochir Suppl (Wien) 1994; 60:3-6
7. Liang D, Bhatta S, Gerzanich V, et al: Cytotoxic edema: Mechanisms of pathological cell swelling. Neurosurg Focus 2007; 22:E2
8. Rubin LL, Staddon JM: The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999; 22:11-28
9. D'Atri F, Citi S: Molecular complexity of vertebrate tight junctions (Review). Mol Membr Biol 2002; 19:103-112
10. Förster C: Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 2008; 130:55-70
11. Papadopoulos MC, Manley GT, Krishna S, et al: Aquaporin-4 facilitates reabsorption of excess fuid in vasogenic brain edema. FASE B J 2004; 18:1291-1293
12. Bloch O, Manley GT: The role of aquaporin-4 in cerebral water transport and edema. Neurosurg Focus 2007; 22:E3
13. Hall ED: The neuroprotective pharmacology of methylprednisolone. J Neurosurg 1992; 76:13-22
14. Reichardt HM, Gold R, Lühder F: Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert Rev Neurother 2006; 6:1657-1670
15. Forster C, Burek M, Romero IA, et al. Glucocorticoids and TNFal-pha act differently on brain endothelial tight junction proteins in an in vitro model of human Blood-Brain Barrier. J Physiol 2008; 586.7:1937-1949.
16. Förster C, Silwedel C, Golenhofen N, et al: Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol (Lond) 2005; 565(Pt 2):475-486
17. Harke N, Leers J, Kietz S, et al. Identifcation of a distal glucocorti-coid responsive element in the occludin gene coding region. Mol Cell Endocrinol 2008; 295:39-47
18. Blecharz KG, Drenckhahn D, Förster CY: Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. J Cereb Blood Flow Metab 2008; 28: 1139-1149
19. Förster C, Kahles T, Kietz S, et al: Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol (Lond) 2007; 580(Pt.3): 937-949
20. Rosenberg GA: Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009; 8:205-216
21. Zeni P, Doepker E, Schulze-Topphoff U, et al: MMPs contribute to TNF-alpha-induced alteration of the blood-cerebrospinal fuid barrier in vitro. Am J Physiol, Cell Physiol 2007; 293:C855-C864
22. Burnham JA, Wright RR, Dreisbach J, et al: The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991; 41:1349-1354
23. Poungvarin N: Steroids have no role in stroke therapy. Stroke 2004; 35:229-230
24. Saul TG, Ducker TB, Salcman M, et al: Steroids in severe head injury: A prospective randomized clinical trial. J Neurosurg 1981; 54:596-600
25. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury. XV. Steroids. J Neurotrauma 2007; 24(Suppl 1):S91-95.
26. Wallace AD, Cidlowski JA: Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocor-ticoids. J Biol Chem 2001; 276:42714-42721
27. Beato M, Klug J: Steroid hormone receptors: An update. Hum Reprod Update 2000; 6:225-236
28. Taylor AN, Rahman SU, Tio DL, et al: Injury severity differentially alters sensitivity to dexamethasone after traumatic brain injury. J Neu-rotrauma 2010; 27:1081-1089
29. Hwang IK, Yoo KY, Nam YS, et al: Mineralocorticoid and glucocor-ticoid receptor expressions in astrocytes and microglia in the gerbil hippocampal CA1 region after ischemic insult. Neurosci Res 2006; 54:319-327
30. Blecharz K, Burek M, Bauersachs J, et al. Inhibition of proteasome-mediated glucocorticoid receptor degradation restores nitric oxide bioavailability in myocardial endothelial cells. British Journal of Pharmacology 2011; submitted.
31. Förster C, Waschke J, Burek M, et al: Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain spe-cifc. J Physiol (Lond) 2006; 573(Pt 2):413-425
32. Kleinschnitz C, Blecharz K, Kahles T, et al: Glucocorticoid insensitivity at the hypoxic blood-brain barrier can be reversed by inhibition of the proteasome. Stroke 2011; 42:1081-1089
33. Thal SC, Wyschkon S, Pieter D, et al: Selection of endogenous control genes for normalization of gene expression analysis after experimental brain trauma in mice. J Neurotrauma 2008; 25:785-794
34. Paramore A, Frantz S: Bortezomib. Nat Rev Drug Discov 2003; 2:611-612
35. Henninger N, Sicard KM, Bouley J, et al: The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia. Neurosci Lett 2006; 398:300-305
36. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613
37. Schmidt-Kastner R, Meller D, Bellander BM, et al: A one-step immuno-histochemical method for detection of blood-brain barrier disturbances for immunoglobulins in lesioned rat brain with special reference to false-positive labelling in immunohistochemistry. J Neurosci Methods 1993; 46:121-132
38. Tanno H, Nockels RP, Pitts LH, et al: Breakdown of the blood-brain barrier after fuid percussive brain injury in the rat. Part 1: Distribution and time course of protein extravasation. J Neurotrauma 1992; 9:21-32
39. Thal SC, Sporer S, Schmid-Elsaesser R, et al: Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med 2009; 37:2228-2234
40. Tsenter J, Beni-Adani L, Assaf Y, et al: Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions. J Neurotrauma 2008; 25:324-333
41. Unterberg AW, Stover J, Kress B, et al: Edema and brain trauma. Neu-roscience 2004; 129:1021-1029
42. Zhou J, Cidlowski JA: The human glucocorticoid receptor: One gene, multiple proteins and diverse responses. Steroids 2005; 70:407-417
43. Tronche F, Kellendonk C, Reichardt HM, et al: Genetic dissection of glucocorticoid receptor function in mice. Curr Opin Genet Dev 1998; 8:532-538
44. Adcock IM, Barnes PJ: Molecular mechanisms of corticosteroid resistance. Chest 2008; 134:394-401
45. McCullers DL, Sullivan PG, Scheff SW, et al: Traumatic brain injury regulates adrenocorticosteroid receptor mRNA levels in rat hippocampus. Brain Res 2002; 947:41-49
46. Lee BH, Wen TC, Rogido M, et al: Glucocorticoid receptor expression in the cortex of the neonatal rat brain with and without focal cerebral ischemia. Neonatology 2007; 91:12-19
47. Sapolsky RM, Krey LC, McEwen BS: Stress down-regulates corticos-terone receptors in a site-specifc manner in the brain. Endocrinology 1984; 114:287-292
48. Dou QP, Goldfarb RH: Bortezomib (millennium pharmaceuticals). IDrugs 2002; 5:828-834
49. Sauerbeck A, Gao J, Readnower R, et al: Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and infammation following traumatic brain injury. Exp Neurol 2011; 227:128-135
50. Lahiri S, Sen T, Palit G: Involvement of glucocorticoid receptor and per-oxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats. Eur J Pharmacol 2009; 609: 118-125
51. Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System. Second Edition. Philadelphia, PA: WB Saunders Co, 1992
52. Yang Y, Rosenberg GA: Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011; 42:3323-3328
53. Edwards P, Arango M, Balica L, et al; CRASH trial collaborators: Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005; 365:1957-1959